

Informazione Regolamentata n. 0957-4	Data/Ora Inizio Diffusione 18 Gennaio 2024 12:25:56	Euronext Milan
--	--	----------------

Societa' : DIASORIN

Identificativo Informazione
Regolamentata : 185427

Nome utilizzatore : Ulisse Spada - Valerio Giovanni Vaccarone

Tipologia : REGEM

Data/Ora Ricezione : 18 Gennaio 2024 12:25:56

Data/Ora Inizio Diffusione : 18 Gennaio 2024 12:25:56

Oggetto : DiaSorin S.p.A. - 2024 Annual Calendar of
Corporate Events

Testo del comunicato

See attachment.

DIASORIN S.P.A. - 2024 ANNUAL CALENDAR OF CORPORATE EVENTS

Saluggia - January 18, 2024

Board of Directors

March 15, 2024	Draft Statutory Financial Statements 2023 and Consolidated Financial Statements 2023 approval
May 10, 2024	First Quarter 2024 results approval
August 1, 2024	Half-Yearly Financial Report approval
November 15, 2024	Third Quarter 2024 results approval

Shareholders' Meeting

April 24, 2024	Annual General Meeting for: (i) Statutory Financial Statements 2023 approval; (ii) Report on the remuneration policy and fees paid approval; (iii) appointment of the audit firm for fiscal years 2025-2033.
-----------------------	---

Indicative dates subject to change. Any changes will be communicated without delay.

The Company informs that the month envisaged for the payment of any dividend in relation to 2023 results is May 2024. The information herein reported is given for the exclusive purpose of complying with the relevant Borsa Italiana S.p.A. regulations and cannot be interpreted or considered in any way as a forecast on the occurrence of the requirements for the distribution of dividends.

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 35 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasorin.com

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

INVESTOR RELATIONS

Riccardo Fava

Corporate VP Communication, ESG & Investor Relations
riccardo.fava@diasorin.it

Eugenia Ragazzo

Corporate Investor Relations & ESG Analyst
eugenia.ragazzo@diasorin.it

Fine Comunicato n.0957-4

Numero di Pagine: 3